Associate Director, HEOR & Access

Indeg Sly

She has led the economic development of numerous HTA submissions, predominantly submissions to NICE. Worked on >20 cost-effectiveness models including discrete event simulations, in addition to early CE modelling projects. Indeg has conducted extensive analyses in R including patient-level propensity score matching and survival analysis.
Indeg has over 8 years’ experience in HEOR and market access across consultancy and the NHS.

Key facts

Has led clinical advisory boards, Delphi panels and KOL interviews
She has contributed to the development of a utility vignette study.
Worked on multi million commercial deals between the pharma industry and the NHS
Including BIT, MAA, CDF, HST and innovative pricing deals. Prior to this, Indeg worked for a HEOR consultancy for >5 years.
Holds an MSc in Health Economics and Decision Modelling from the University of Sheffield
And a BSc in Mathematics and Philosophy from the University of Sheffield.
Experience in range of therapy areas:
  • Oncology (multiple myeloma, ovarian, breast)
  • Crohn’s Disease
  • Myelofibrosis
  • Rare/orphan diseases, including Spinal Muscular Atrophy
  • Peanut allergy